This was on last week’s insider buying list and the recent purchases make the stock look interesting. It’s not a Ben Graham stock but instead has potential products that MAY have significant market potential relative to the current price. Glenhill Advisors also made a recent large investment with a +10% ownership.
A recent private placement during February raised an additional 5.80 million. The clinical trials could have a high probability of success given the recent private placement but I don’t know.
Please do your own work as this stock is risky with little traditional margin of safety.
NMT Medical Announces $5.8 Million Financing